Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Press release Link